# A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

Source: https://onco.cc/trials/nct07213804/  
OnCo record `nct07213804` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Sofetabart Mipitecan in ovarian cancer, now recruiting.

## Summary

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer is a phase 3 interventional study registered as NCT07213804, led by Eli Lilly and with GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT) and Asia-Pacific Gynecologic Oncology Trials, and recruiting on the registry. Official title: FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer. Planned enrolment is 1630 participants (estimated). The study started in 2025-10-22 and primary completion is expected in 2028-11. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: FRAmework-01
- Tags: ctgov-ingest
- Registry id: NCT07213804
- Phase: 3
- Setting: FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer
- Sponsor: Eli Lilly and
- Enrolled: 1630

## Sources

- ClinicalTrials.gov NCT07213804: https://clinicaltrials.gov/study/NCT07213804

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Sofetabart Mipitecan](https://onco.cc/drugs/sofetabart-mipitecan/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/)

---
JSON: https://onco.cc/api/v1/entities/nct07213804.json